Benzinga | Jan 6, 2022 07:06AM EST

IN8bio Announces Clinical Updates From The Phase 1 Clinical Trial Of Its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

* INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort

* Cohort 1 dosing is complete with three patients who received a single dose of INB-200 with no dose limiting toxicities (DLTs), cytokine release syndrome (CRS), or neurotoxicity, and a manageable safety profile

* Cohort 2 is enrolling with one patient having received all three doses of INB-200, the first-ever repeat dosing of genetically modified gamma-delta T cells

* Of the four patients treated to date, all have exceeded their expected progression-free survival (PFS) interval, with an encouraging trend in OS1-3